Recently, studies were investigated on belzutifan, development code: MK-6482, which is a hypoxia-inducible factor-2α (HIF-2α) inhibitor for the treatment of adult patients with Hippel-Lindau syndrome. This evidence concerns the gene EPAS1 and von Hippel-Lindau disease.